GlaxoSmithKline (GSK) is focusing on a completely new technique to treat diseases i. e. by making electrical signals in the body the target.
It has been found that a small bet is, therefore, being put on the new way by the company. On Wednesday, it has been announced that a $1 million prize would be given to the one, who incites innovation in the area.
The biggest drugmaker of Britain also declared that some 40 researchers would be funded, who have been working in external laboratories.
According to the report, the initiative being taken is a long-term gamble on a new kind of medicine's promise. The medicine does not use biological molecules or the chemicals usually found in the drugs today. Rather, electrical impulses are being focused at.
It is the belief of GSK that the medicine would take it ahead of its rivals in the market. Since, the work is in its early stage in the emerging field, the company is hoping to play a significant role by bringing researchers together.
"At GlaxoSmithKline and in academia, we are confident that this field will deliver real medicines, and we are mobilizing resources for this journey", said Kristoffer Famm, GSK head of bioelectronics research.
- Postage Prices will Decrease from Sunday; USPS not too Happy About It
- Marriott and Starwood Hotels & Resorts Worldwide Inc Shareholders Approve to $14.41 Sales Deal
- UK plan to impose additional tax on sugary drinks
- Obesity during pregnancy may increase risk of very ‘large babies’
- Dropping Sales at Gap’s Key Brands hurt the Company’s Shares